Breaking News

Financial Report: AbbVie

By Kristin Brooks | January 31, 2014

Revenues down 2% in the quarter

AbbVie
 
4Q Revenues: $5.1 billion (-2%)
 
4Q Earnings:
$1.1 billion (-27%)
 
FY Revenues: $18.8 billion (+2%)
 
FY Earnings: $4.1 billion (-22%)
 
Comments: Global Humira sales increased 13% to $3.0 billion in the quarter. U.S. Humira sales grew 18% to $1.7 billion. Synagis sales were $314 million, down 6%. AndroGel sales were down 21% to $289 million. Kaletra sales were $228 million, down 9%. Lupron sales were $209 million, down 1%. Synthroid sales were up 13% to $189 million. Niaspan and TriCor/Trilipix sales were down 89% and 85% respectively, due to generic competition. R&D expenses were up 17% to $798 million in the quarter.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks